
The role of Janus kinase inhibitors
Povorcitinib was studied in a phase 3 trial at 45 milligrams (mg) and 75 mg doses, and upadacitinib is also assessed in phase 3 for hidradenitis suppurativa, Porter said.
Episodes in this series

Povorcitinib was studied in a phase 3 trial at 45 milligrams (mg) and 75 mg doses, and upadacitinib is also assessed in phase 3 for hidradenitis suppurativa, Porter said. The povorcitinib phase 3 data look broadly similar to those for secukinumab [sold under the brand name Costenyx] for the disease, she observed. Because JAK inhibitors don’t overlap much mechanistically with interleukin-17 or TNF-alpha inhibitors, patients previously treated with biologics and who were more treatment refractory did as well as the overall cohort. Data presented at the 2026 European Academy of Dermatology and Venereology Congress showed that patients with a high burden of draining tunnels did better on the 75 mg dose of povorcitinib. Despite a hidradenitis suppurativa population with a higher baseline risk of clots and cardiovascular events, the povorcitinib safety profile looked quite good, she said. Porter expects dermatologists will still prefer to give biologics first because of safety concerns, as in other disease states.
Related to this article








